Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)

Market Cap	89.14B
Revenue (ttm)	2.49B
Net Income (ttm)	-294.04M
Shares Out	1.27B
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	48.64
Dividend	0.32 (0.45%)
Ex-Dividend Date	n/a

Volume	2,414,835
Open	72.99
Previous Close	72.99
Day's Range	72.02 - 73.29
52-Week Range	47.62 - 89.89
Beta	2.20
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 12, 2025

About Beijing Wantai Biological Pharmacy Enterprise

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. The company was founded in 1991 and is headquartered in Beijing, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 3,843
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603392

Financial Performance

In 2023, Beijing Wantai Biological Pharmacy Enterprise's revenue was 5.51 billion, a decrease of -50.73% compared to the previous year's 11.19 billion. Earnings were 1.25 billion, a decrease of -73.65%.